Compare Palantir Technologies Inc (PLTR) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Palantir Technologies Inc vs Zimmer Biomet Holdings Inc — how do they compare? Palantir Technologies Inc trades at $169.42 (market cap $409.24B), while Zimmer Biomet Holdings Inc trades at $94.73 (market cap $17.97B). The key difference: Palantir Technologies Inc is far larger — about 22.8× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.02% dividend while Palantir Technologies Inc pays none. Which is the better fit depends on your goals.
| PLTR | ZBH | |
|---|---|---|
Market Cap | $409.24B | $17.97B |
Sector | Technology | Health |
52-Week High | $207.18 | $104.26 |
52-Week Low | $107.27 | $79.58 |
Enterprise Value | $400.04B | $25.04B |
Dividend Yield | — | 1.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Palantir (PLTR) trades at $170.30, down 2.31% on the day, with technical indicators showing neutral signals amid strong fundamental performance. The company reported exceptional Q2 2026 results with EPS of $0.41 beating expectations by 19%, while revenue growth accelerated to 93% year-over-year. Recent news highlights the strategic Nebius partnership for sovereign AI infrastructure, positioning Palantir to address growing enterprise demand for private AI deployment solutions.
While valuation metrics remain elevated with P/E of 145.6 and P/S of 71.1, the company's 49% net margin and 38.4% ROE demonstrate strong profitability. The consensus price target of $211.38 suggests 24% upside potential, though competitive pressures and high expectations create execution risks. Investors face the tension between premium valuation and exceptional growth trajectory.
Zimmer Biomet (ZBH) trades at $94.22, down 3.93% on the day, with a bearish technical signal but strong fundamentals including a 69.87% gross margin and three consecutive quarterly earnings beats. Revenue growth is steady, reaching $8.23B in 2025, though net income margin dipped to 8.56%. Recent leadership promotions aim to accelerate commercial transformation, while analyst consensus price target is $104.88, implying 11.3% upside.
The stock presents a value opportunity with a P/E of 22.87 and P/S of 2.17, supported by robust cash flow and dividend payments. Risks include rising debt-to-asset ratio (32.57% in 2025) and competitive pressures. Wall Street sentiment is mixed with 40.48% buy ratings, but technical indicators suggest near-term caution amid bearish moving averages.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Palantir Technologies Inc
Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
